Keywords: Teva Pharma Industries, 2012 financial forecast
Teva lowers full-year 2012 forecasts
Article | 25 May 2012
Israel-based generic drug major Teva Pharmaceutical Industries (Nasdaq: TEVA) has provided its current outlook for non-GAAP financial performance for the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
